CHAPTER 1. Industry Overview of Bleeding Disorder Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Bleeding Disorder Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Bleeding Disorder Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Bleeding Disorder Treatment Market By Type
1.2.3. Bleeding Disorder Treatment Market By Drug Class
1.2.4. Bleeding Disorder Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Bleeding Disorder Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Bleeding Disorder Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Bleeding Disorder Treatment Market By Type
4.1. Introduction
4.2. Bleeding Disorder Treatment Revenue By Type
4.2.1. Bleeding Disorder Treatment Revenue (USD Million) and Forecast, By Type, 2018-2030
4.2.2. Hemophilia A
4.2.2.1. Hemophilia A Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Hemophilia B
4.2.3.1. Hemophilia B Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Von Willebrand Disease (vWD)
4.2.4.1. Von Willebrand Disease (vWD) Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Bleeding Disorder Treatment Market By Drug Class
5.1. Introduction
5.2. Bleeding Disorder Treatment Revenue By Drug Class
5.2.1. Bleeding Disorder Treatment Revenue (USD Million) and Forecast, By Drug Class, 2018-2030
5.2.2. Plasma Derived Coagulation Factor Concentrates
5.2.2.1. Plasma Derived Coagulation Factor Concentrates Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Recombinant Coagulation Factor Concentrate
5.2.3.1. Recombinant Coagulation Factor Concentrate Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.4. Antifibrinolytic
5.2.4.1. Antifibrinolytic Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.5. Desmopressin
5.2.5.1. Desmopressin Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.6. Fibrin Sealants
5.2.6.1. Fibrin Sealants Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.7. Others
5.2.7.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Bleeding Disorder Treatment Market By Country
6.1. North America Bleeding Disorder Treatment Market Overview
6.2. U.S.
6.2.1. U.S. Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
6.2.2. U.S. Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.3. Canada
6.3.1. Canada Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
6.3.2. Canada Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Bleeding Disorder Treatment Market By Country
7.1. Europe Bleeding Disorder Treatment Market Overview
7.2. U.K.
7.2.1. U.K. Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
7.2.2. U.K. Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.3. Germany
7.3.1. Germany Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
7.3.2. Germany Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
France
7.3.3. France Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
7.3.4. France Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.4. Spain
7.4.1. Spain Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
7.4.2. Spain Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.5. Rest of Europe
7.5.1. Rest of Europe Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
7.5.2. Rest of Europe Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.6. Europe PEST Analysis
CHAPTER 8. Asia Pacific Bleeding Disorder Treatment Market By Country
8.1. Asia Pacific Bleeding Disorder Treatment Market Overview
8.2. China
8.2.1. China Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.2.2. China Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.3. Japan
8.3.1. Japan Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.3.2. Japan Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.4. India
8.4.1. India Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.4.2. India Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.5. Australia
8.5.1. Australia Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.5.2. Australia Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.6. South Korea
8.6.1. South Korea Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.6.2. South Korea Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
8.7.2. Rest of Asia-Pacific Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Bleeding Disorder Treatment Market By Country
9.1. Latin America Bleeding Disorder Treatment Market Overview
9.2. Brazil
9.2.1. Brazil Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
9.2.2. Brazil Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.3. Mexico
9.3.1. Mexico Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
9.3.2. Mexico Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
9.4.2. Rest of Latin America Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Bleeding Disorder Treatment Market By Country
10.1. Middle East & Africa Bleeding Disorder Treatment Market Overview
10.2. GCC
10.2.1. GCC Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
10.2.2. GCC Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.3. South Africa
10.3.1. South Africa Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
10.3.2. South Africa Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Type, 2018-2030
10.4.2. Rest of Middle East & Africa Bleeding Disorder Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Bleeding Disorder Treatment Market
11.1. Bleeding Disorder Treatment Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Type Launches and Type Enhancements
11.2.3. Mergers And Acquisition In Global Bleeding Disorder Treatment Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Sanofi SA
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Million), 2021
12.1.3.2. Sanofi SA 2021 Bleeding Disorder Treatment Business Regional Distribution
12.1.4. Type/Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Swedish Orphan Biovitrum AB
12.3. Janssen Pharmaceuticals, Inc.
12.4. Baxter International Inc.
12.5. Pfizer Inc.
12.6. Genentech, Inc.
12.7. CSL Behring
12.8. Novo Nordisk
The estimated value of global bleeding disorder treatment market in 2021 was accounted to be USD 13,570 Million.
The projected CAGR bleeding disorder treatment market during the analysis period of 2022 to 2030 is 7.8%.
The prominent players of the global bleeding disorder treatment market are Sanofi SA, Swedish Orphan Biovitrum AB, Janssen Pharmaceuticals, Inc., Baxter International Inc., Pfizer Inc., Genentech, Inc., CSL Behring, and Novo Nordisk.
North America held the dominating bleeding disorder treatment during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for bleeding disorder treatment during the analysis period of 2022 to 2030.
Increasing R&D investment in hemophilia product development and growing number of individuals with hemophilia diagnoses drives the growth of global bleeding disorder treatment market.
Based on type, hemophilia A segment is expected to hold the maximum share of the bleeding disorder treatment market.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date